We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.40 | -0.50% | 275.97 | 275.90 | 276.05 | 278.515 | 275.10 | 277.69 | 881,184 | 17:30:20 |
From May 2022 to May 2024
By Colin Kellaher
Amgen Inc. on Monday said the U.S. Food and Drug Administration approved the expanded use of its Riabni biosimilar to Rituxan in certain patients with the chronic inflammatory joint disease rheumatoid arthritis.
Amgen said the approval covers Riabni in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor antagonist therapies.
Biosimilars are near-copies of biologic drugs, such as Rituxan, that are made from living cells and are analogous to generic copies of traditional medicines.
Rituxan is jointly marketed by Biogen Inc. and Roche Holding AG's Genentech unit.
The FDA previously approved Riabni for the treatment of adults with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (also called Wegener's granulomatosis) and microscopic polyangiitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 06, 2022 09:35 ET (13:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
